
A new kind of non-opioid painkiller gets FDA approval
In 2024, the drug company Vertex Pharmaceuticals reported that Journavx reduced pain compared with a placebo in people who had abdominal or foot surgery, although the effect was modest.
In 2024, the drug company Vertex Pharmaceuticals reported that Journavx reduced pain compared with a placebo in people who had abdominal or foot surgery, although the effect was modest.
One large study examining evidence of antibodies against the coronavirus found that by the fall of 2022 more than 96 percent of people in the United States had immunity from vaccination, prior infection or both.